Expertise in
7
conditions

Dr. Barry Horowitz

Palm Beach Diabetes And Endocrine Specialists PA
Jupiter, FL
Expertise in
7
conditions
Specialties:Endocrinology
Offers Telehealth
Expertise in
7
conditions
OverviewInsuranceLocationsClinical Research

Overview

Barry Horowitz is an Endocrinologist in Jupiter, Florida. MD. Horowitz is highly rated in 7 conditions, according to our data. His top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, and Obesity in Children.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in FL
Hospital Affiliations
Jupiter Medical Center
Good Samaritan Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health Options
  •  Oscar
  •  Humana
  •  Florida Blue

Locations

PALM BEACH DIABETES AND ENDOCRINE SPECIALISTS PA
1210 S Old Dixie Hwy, Jupiter, FL 33458
561-659-6336
Other Locations
PALM BEACH DIABETES AND ENDOCRINE SPECIALISTS PA
550 Heritage Dr, Suite 150, Jupiter, FL 33458
561-659-6336
PALM BEACH DIABETES AND ENDOCRINE SPECIALISTS PA
1515 N Flagler Dr, Suite 430, West Palm Beach, FL 33401
561-659-6336
PALM BEACH DIABETES AND ENDOCRINE SPECIALISTS PA
6056 Boynton Beach Blvd, Suite 245, Boynton Beach, FL 33437
561-639-6336

Additional Areas of Focus

Dr. Horowitz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Suspended
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 01, 2021
Intervention Type: Device
Study Phase: Not Applicable
An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes
An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

6 Total Publications

Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.
Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.
Journal: Diabetes technology & therapeutics
Published: March 09, 2022
Similar Doctors
Expertise in
26
conditions
Dr. Aleksandra Kraeher
Endocrinology
Expertise in
26
conditions
Dr. Aleksandra Kraeher
Endocrinology

Aleksandra Kraeher MD PA

4600 Military Trl, Suite 218, 
Jupiter, FL 
 (2.1 mi)
561-626-9041
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aleksandra Kraeher is an Endocrinologist in Jupiter, Florida. Dr. Kraeher is highly rated in 26 conditions, according to our data. Her top areas of expertise are Hypothyroidism, Obesity in Children, Diabetic Nephropathy, and Osteoporosis.

Expertise in
24
conditions
Dr. Jay Waddadar
Endocrinology
Expertise in
24
conditions
Dr. Jay Waddadar
Endocrinology

Martin Memorial Physician Corporation Inc

2150 Se Salerno Rd, 
Stuart, FL 
 (16.6 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jay Waddadar is an Endocrinologist in Stuart, Florida. Dr. Waddadar is highly rated in 24 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Thyroid Nodule, Obesity in Children, and Diabetic Neuropathy.

Expertise in
34
conditions
Dr. Alan Feldman
Endocrinology
Expertise in
34
conditions
Dr. Alan Feldman
Endocrinology

Aleksandra Kraeher MD PA

4600 Military Trl, Suite 218, 
Jupiter, FL 
 (2.1 mi)
561-626-9041
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alan Feldman is an Endocrinologist in Jupiter, Florida. Dr. Feldman is highly rated in 34 conditions, according to our data. His top areas of expertise are Hyperparathyroidism, Postmenopausal Osteoporosis, Osteoporosis, and Parathyroid Hyperplasia.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile